Development and validation of a novel panel of 16 STR markers for simultaneous diagnosis of β-thalassemia, aneuploidy screening, maternal cell contamination detection and fetal sample authenticity in PND and PGD/PGS cases

Zohreh Sharifi1,2, Faezeh Rahiminejad1, Atefeh Joudaki3, Ameneh Sarhadi Bandehi1, Hossein Farahzadi3, Yeganeh Keshvar1, Fatemeh Golnabi1, Sanaz Naderi1, Rasaneh Yazdani1, Mehdi Shafata1, Shiriin Ghadami4, Maryam Abiri5 & Sirous Zeinali1,6

Prenatal diagnosis (PND) may be complicated with sample mix-up; maternal cell contamination, non-paternity and allele drop out at different stages of diagnosis. Aneuploidy screening if combined with PND for a given single gene disorder, can help to detect any common aneuploidy as well as aiding sample authenticity and other probable complications which may arise during such procedures. This study was carried out to evaluate the effectiveness of a novel panel of STR markers combined as a multiplex PCR kit (HapScreen™ kit) for the detection of β-thalassemia, aneuploidy screening, ruling in/out maternal cell contamination (MCC), and sample authenticity. The kit uses 7 STR markers linked to β-globin gene (HBB) as well as using 9 markers for quantitative analysis of chromosomes 21, 18, 13, X and Y. Selection of the markers was to do linkage analysis with β-globin gene, segregation analysis and to perform a preliminary aneuploidy screening of fetal samples respectively. These markers (linked to the β-globin gene) were tested on more than 2185 samples and showed high heterozygosity values (68.4–91.4%). From 2185 fetal cases we found 3 cases of non-paternity, 5 cases of MCC, one case of sample mix-up and one case of trisomy 21 which otherwise may have end up to misdiagnosis. This kit was also successfully used on 231 blastomeres for 29 cases of pre-implantation genetic diagnosis (PGD) and screening (PGS). The markers used for simultaneous analysis of haplotype segregation and aneuploidy screening proved to be very valuable to confirm results obtained from direct mutation detection methods (i.e. ARMS, MLPA and sequencing) and aneuploidy screening.

1Dr. Zeinali’s Medical Genetics Laboratory, Kawsar Human Genetics Research Center, Tehran, Iran. 2Faculty of Advanced Sciences and Technology, Department of Genetics, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. 3Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 4Noor Human Genetic Research Center, Tehran, Iran. 5Department of Medical Genetics and Molecular Biology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. 6Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. Zohreh Sharifi, Hossein Farahzadi and Sirous Zeinali contributed equally. Correspondence and requests for materials should be addressed to M.A. (email: Abiri.m@iums.ac.ir) or S.Z. (email: zeinalipasteur@yahoo.com)
β-thalassemia (β-thal) is the most common autosomal recessive disease in the world, particularly in the Middle East. It is estimated that there are nearly 80 million carriers of β-thal worldwide. There would be approximately 60,000 affected babies born annually worldwide if no prevention program was implemented. Carrier prevalence in Iran, with a population of about 80 million, is estimated to be 3–4 million (4–5%), with a broad spectrum of mutations. Considering 1.5 million births per year, one would expect to see birth of about 700–800 affected children, however, this number has been reduced to less than 150 since a nationwide prevention program was implemented.

PND (prenatal diagnosis) is the method of choice for the prevention of new cases in carrier couples. PND has been in practice for the past several decades and as early as 1993 in Iran. PND is a complicated process which poses misdiagnosis for various reasons including sample mix-up, non-paternity, maternal cell contamination, etc. Evaluation of the mentioned issues is essential in most PND cases and requires time and money otherwise misdiagnosis may occur.

PND usually requires invasive fetal sampling; therefore, to prevent invasive fetal sampling, preimplantation genetic diagnosis (PGD) is used as an established procedure to detect genetic disorders at the embryonic stage. PGD enables us to simultaneously check blastomeres for the disease gene alone or combined with HLA typing (using linked STR markers for haplotyping), aneuploidy detection and gender selection.

In more than a decade, clinical validity of QF-PCR has been established as a rapid technique for aneuploidy diagnosis or exclusion of aneuploidy of chromosomes 13, 18, 21, X or Y for at-risk pregnancies as well as in PGS (preimplantation genetic screening). In most western and many other countries including Iran, every pregnant woman has to be screened for chromosomal aneuploidy.

In this research, we validated a panel of multiplex-PCR based STR genotyping kit (i.e. Hapscreen kit from Genetek Biopharma, Berlin, Germany, GT) which uses STR markers closely linked to the β-globin gene to aid the diagnose of β-thal as a linkage approach for increasing the accuracy of results obtained by direct method (e.g. Sanger sequencing, MLPA or ARMS methods). According to the manufacturer’s claim, to enhance the functionality of this panel, different markers from chromosomes of 13, 18, 21, X, and Y have been added to the above panel. Addition of the mentioned markers facilitate aneuploidy screening, detecting maternal cell contamination, confirming fetal sample authenticity in addition to the diagnosis of β-thal simultaneously.

Materials and Methods

Samples preparation. The study was approved by the ethics committee of Kawsar Human Genetic Research Center. We confirm that all methods were performed in accordance with the relevant guidelines, regulations or protocols. All couples who had applied for PND or PGD were initially visited by a clinical geneticist and their genetic and reproductive history was determined and probable diagnostic choices were discussed.

After obtaining informed consent, different samples from chorionic villus (CV) or blastomeres were obtained by the specialists. DNA was extracted from CV samples using DNA Isolation kit (Kawsar Biotech Co., Tehran, Iran, KBC) following manufacturer’s protocol. Genomic DNA was extracted from blood samples by standard salting out method.

STR identification and selection. At initial phase, 15 STR markers linked to the β-globin gene were selected using UniSTS database and UCSC genome browser. Six of the selected STRs markers were novel using TRF (Tandem Repeats Finder). All selected STRs were tri or tetra nucleotide repeats to increase the accuracy of diagnosis and reduce the stutter artifacts. All primers were designed using Gene Runner software v3.05 and synthesized and labeled commercially. The sequences of these primers are in the province of Genetek Biopharma company. Afterward, 100 unrelated healthy individuals were genotyped to assess genotype frequency for each STR marker. Finally, seven markers were chosen to use in kit manufacturing.

Multiplex-PCR. We obtained GT-HapSceen, Aneusure (a QF PCR kit) and GT-Detector (a human DNA profiling kit) Kits form GeneTek (GeneTek Biopharma, Berlin, Germany, GT). Multiplex-PCR optimization was performed for blood samples and single cell blastomeres separately according to manufacturer’s recommendation and protocols (though the manufacturer had not suggested its use in PGD/PGS). PCR products were analyzed on 2% (w/v) agarose gel (KBC) prior to running on Genetic Analyzer 3130 XL (Thermo Fisher Scientific, US, TF) to check the quality of PCR products.

Haplotype phasing. In order to phase haplotypes, we either used information for each marker from couples’ affected child and if there was no child then a carrier (based on CBC and A2 blood test results or confirmed mutation testing) parent of each partner was used. We have the habit in putting the mutated alleles and therefore haplotype on the left side of the bar (based on the affected child’s haplotype and pattern of inheritance, from the father or mother) and draw each allele for each individual and writing the mutation carrying allele on the left side of the bar. This will be carried out until all alleles are place in either side of the bars. However, for chromosome 13, 18, 21, X and Y we only draw alleles based on haplotypes but try to put paternal ones on the left side of the bar.

Fragment analysis. 1 μ of each PCR product was mixed with HiDi Formamide and GT-500 size standard (GT) denatured at 95 °C for 3 min and snap cooled on ice for 5 min. The denatured PCR products were then separated and detected using an ABI 3130 XL or 3500 XL Genetic Analyzer (TF). Data were analyzed using Genemapper software (TF).

Statistical analysis. Allele frequencies for each STR loci, the power of discrimination (PD) and the power of exclusion (PE), were computed using the PowerStatsV12 Software and Gene Alex. The polymorphic information content, the expected and observed heterozygosity, and the deviation from the Hardy–Weinberg equilibrium (HWE) were calculated based on the Fisher’s exact test method.
Results

Prenatal diagnosis and PGD outcomes. Couples who are either confirmed carriers of β-thal or are suspected of being carrier of β-thal are counseled and are referred for PND. Mutation detection is usually carried out by testing both couple or their affected child by either ARMS method, Sanger sequencing or MLPA. We also would haplotype all cases of confirmed β-thal using RFLP or SNP markers linked to β-globin gene.

For haplotyping, we would use phasing information from the couple, their affected child (if present or available) and/or their parents. Haplotyping have been an essential part of our PND for thalassemia and most other diseases. When the Hapscreen kit became available, we switched to Hapscreen for almost every cases of PND. Therefore, every PND is performed using both direct mutation detection and haplotyping.

More than 2185 fetal cases of β-thal have been diagnosed using the above procedures. From these, 528 fetal samples were homozygous normal, 1105 heterozygous carriers and 552 were affected and all of them were referred for therapeutic abortions. On the other hand, 949 out of 2185 cases were screened for aneuploidies using Hapscreen kit. The PND outcomes were 227 homozygous normal, 494 heterozygote and 228 affected fetuses. From 949 fetal cases, 917 were singleton, 31 were twin and one case was triplet. Among 2185 fetal cases we identified 5 cases of non-paternity, 3 cases of sample mix-up (misdiagnosis was prevented based on Hapscreen results), 3 cases of maternal cell contamination (MCC) and one case of trisomy 21 (suggested by Hapscreen result and confirmed by QFPCR). Some of these cases are shown in Figs 1–3 and elaborated below when figures are being explained.

In total, we analyzed more than 238 blastomeres from 29 PGD cases. Our analysis showed that 51 blastomeres were homozygous normal, 82 were carriers, 55 were affected (not transferable) and the rest (50 blastomeres) did not produce any result. This may have been either the sample had been deliberately blanked by the IVF center, or no cells had been transferred into the tubes (either the cell had been lysed before transferring or had been released onto the tubes wall).

In total 124 embryos were transferable, though in few cases the parents had decided only to transfer homozygous normal cells. To date 11 pregnancies had occurred, two was miscarried, 3 are ongoing and 5 healthy babies have been born.

Heterozygosity assessment of the markers. Allele frequencies and heterozygosity of 15 β-globin STR markers were obtained by genotyping 100 unrelated healthy individuals prior to use them in haplotyping fetal samples. In total, 133 different alleles were detected (data is shown in Table 1).

The observed range of allele frequencies varied. According to our study, D11HBBSU3.2 marker had the highest heterozygosity (96.4%) among the 15 studied STR markers. D11HBBSUD1.06 marker with 90.9% frequency was the second most heterozygous marker. The allele size ranges and heterozygosity of STR loci are listed in Table 1. The PD ranges were from 0.76 to 0.93 for D11HBBSUD11.2 and D11HBBSU3.2 loci respectively. Estimating allele and genotype frequencies showed no deviation from the Hardy–Weinberg equilibrium.
Markers used in PND and PGD. Since the initial use of the \( \beta \)-globin HapScreen kit, we have been using it routinely in almost all cases of PNDs for \( \beta \)-thal. It has been extremely valuable to track the disease gene segregation and also confirm results obtained by other methods (e.g., ARMS or Sanger sequencing), paternity, sample authenticity, or even uniparental disomy.\(^{29}\)

Also it has been shown to be extremely valuable when the disease is confirmed by other methods (e.g. CBC, HBA2 level and clinical presentation). Indeed in several cases the initial investigation of the \( \beta \)-globin gene by sequencing or MLPA had not resulted in identifying a definite causal mutation in several families with CBC and HbA2 levels similar to those of \( \beta \)-thal carriers, who had been referred to our lab for either PND or PGD, despite of our center being the most experienced lab in the country.\(^{5}\) Therefore, for the purpose of PND, indirect approaches such as using RFLP, SNP or STR markers can be used.\(^{21,30}\) In addition, 29 other families were considered as a candidate for PGD, with a medical history of at least two abortions due to fetuses being diagnoses as affected with \( \beta \)-thal and parents’ desire was not to go through natural pregnancy which necessitates PND.

Our policy for carrying our PND or PGD is that the haplotypes from family members should be determined to track the mutant allele even before fetal sampling and in every case of PGD before starting IVF procedure.

Below several cases have been given to clearly demonstrate our approaches. For example, Fig. 2 shows results of haplotyping for a \( \beta \)-thal family with a triplet pregnancy. We knew that the person I-1 (the father) carries Fr8–9 mutations. II-1 is a female carrier fetus affected with trisomy 21. II-2 and II-3 are carrier female and male fetuses respectively. The last two fetuses are very similar in their haplotypes. The only difference is in Amelogenin (AmXY) marker which helped us in differentiating these two fetuses from each other. Therefore, confirming sample authenticity and MCC is ruled out for all three fetuses. “NL” means normal or wild type allele. (\( P < 0.001 \)). Other statistical findings are shown in Table 1. Allele frequencies for QF-PCR part of the kit were not calculated, though are available since they are generated simultaneously in every test (Fig. 1) and are available elsewhere since they are commonly used in most commercially available QFPCR kits including AneuSure (GT).\(^{24–28}\)

\[
\begin{array}{c|c|c|c|c|c|c|c|c|c|c|c|c|c}
& \text{Mutation} & \text{Fr8-9} & \text{NL} & \text{IVS-5} & \text{Fr8-9} & \text{IVS-5} & \text{Fr8-9} & \text{IVS-5} & \text{NL} \\
\hline
D1HBBSEU1 & 138 & 164 & 152 & 147 \\
D1HBBSEU4.1 & 136 & 136 & 136 & 144 \\
D1HBBSEU3.2 & 324 & 316 & 316 & 312 \\
D1HBBSEU2.9 & 319 & 321 & 312 & 312 \\
D1HBBSED1.06 & 193 & 173 & 177 & 177 \\
D1HBBSED3.3 & 173 & 160 & 160 & 170 \\
D1HBBSED11.2 & 127 & 127 & 127 & 123 \\
\hline
\end{array}
\]
IVS-1-5 mutation and I-2 (the mother) carries a frameshift 8–9 (Fr8–9) mutation. Haplotyping in the pedigree shows that II-1 is a female carrier fetus affected with trisomy 21. II-2 and II-3 are female and male carrier fetuses respectively. The last two fetuses are very similar in their haplotypes. The only difference is in their Amelogenin (AmXY) region which helped us to differentiate these two fetuses from each other (confirming sample not being mixed-up). Other confirmatory test also confirmed sex typing results. Sample authenticity is confirmed by shared alleles between the parents and fetuses and also MCC is ruled out for all three fetuses.

In Fig. 3 we have another case of β-thal. In this case, haplotyping confirmed non-paternity. Since the carrier couple shares the same mutation and haplotype, the fetus shares one of the haplotypes but the other one is not present in either the mother or the father, confirming non-paternity but sample authenticity since it had maternal haplotype. No chromosomal aneuploidy was observed. We do not have the habit in informing the parents in non-paternity cases, though no official rule is in place to follow. Having extra markers from the Aneusure QF-PCR kit (GT) included in this panel provided us the opportunity to rule out or confirm sample authenticity and non-paternity. For further confirmation, paternity testing was performed using GT-Detector kit (GT). As presented in Fig. 4, the paternity was rejected by this approach as well.

The final example is a case of PGD for β-thal which is shown in Fig. 5. II-7 and II-9 blastomeres are not affected with thalassemia but they suffer from monosomy of 21 and trisomy of 21 respectively. Therefore, the only four transmissible blastomeres were II-3, II-4, II-6 and II-8.

Figure 3. A β-thalassemia PND case from CVS which demonstrates sample authenticity dispute. It shows that the fetus (II-2) does not share some of his haplotypes from his father (lacking shared haplotype [with mutation] from his father if the red haplotype is from the mother). Discrepancy in other marks on different chromosomes (13, 18 and 21) showed this fetus is not the biological child of the father. “NL” means normal or wild type allele.
Discussion

β-thal is the most common hematological disorder in the Middle Eastern countries\textsuperscript{31}. National Program for the Prevention of Thalassemia has been in effect since 1997 in Iran\textsuperscript{5,6}. Since then, many different types of mutation have been diagnosed\textsuperscript{32}. However, there still exist cases with hematological parameters indicating β-thal but no mutation can be found despite using all available techniques like sequencing, gap PCR, MLPA and NGS\textsuperscript{33,34}. We showed that using STR markers can be very helpful in several ways for performing either PGDs\textsuperscript{35} or in special cases of PNDs where hematological indices indicate that the parents are carrier/s of β-thal\textsuperscript{36}, even when no mutation can be found using techniques like whole gene sequencing or MLPA\textsuperscript{37}. In addition, haplotype analysis can be helpful when there is a time constraint to find the mutation and even confirming direct mutation analysis findings\textsuperscript{38}.

Although linkage analysis is very practical, it has some limitations such as some markers may not be informative in some families or no other number of the family is available for genotyping\textsuperscript{39,40}. The performance of...
homozygosity mapping is highly depending on markers heterozygosity. Another limitation is that it can't be used if involvement of beta-globin gene is not 100% confirmed.

Regarding aborting affected fetuses, there is a religious decree and also a law allowing legal abortion in Iran. The law has been in effect since 2006 and religious decree since 19964. For PGDs we have the habit to ask the family to undergo PND at 11–16 weeks' gestation to avoid any misdiagnosis either at molecular stage or at embryo transfer. To date we have not had any misdiagnosis for beta-thalassemia and also if a family refuses to do PND, the assigned haplotypes are shown underneath each blastomere, parents and the affected child. The order of corresponding STR markers are shown on left.

Table 1. Statistical findings of HBB STR markers. PD stands for power of discrimination, PE: power of exclusion, PIC: polymorphic information content, Het obs: observed heterozygosity, Het exp: expected heterozygosity, PHWE: significance of deviation from Hardy–Weinberg equilibrium.

| Incl | D11HB BSD0.4 | D11HB BSD3.3 | D11HB BSU.9 | D11HB BSU31.0 | D11HB BSU11.0 | D11HB BSU11.0 | D11HB BSD0.6 | D11HB BSD2.1 | D11HB BSU15.6 | D11HB BSD3.1 | D11HB BSD15.6 | D11HB BSD1.06 | D11HB BSD3.2 |
|------|--------------|--------------|-------------|--------------|-------------|--------------|--------------|--------------|--------------|-------------|--------------|--------------|--------------|--------------|
| Size range | 290–325 | 140–200 | 300–360 | 120–180 | 210–290 | 125–210 | 305–348 | 238–275 | 264–292 | 208–295 | 337–375 | 196–224 | 166–194 | 140–220 | 300–384 |
| Matching Probability | 0.109 | 0.067 | 0.171 | 0.15 | 0.081 | 0.13 | 0 | 0.069 | 0.083 | 0.068 | 0.108 | 0.16 | 0.068 | 0.094 |
| Expressed as 1 in... | 9.2 | 14.9 | 5.9 | 6.7 | 6.7 | 12.3 | 11.5 | 6.6 | 14.5 | 12 | 15.1 | 9.1 | 6.1 | 14.8 | 10.6 |
| PD* | 0.857 | 0.924 | 0.868 | 0.866 | 0.761 | 0.908 | 0.921 | 0.771 | 0.925 | 0.917 | 0.881 | 0.854 | 0.865 | 0.932 | 0.906 |
| PIC | 0.74 | 0.78 | 0.64 | 0.69 | 0.75 | 0.77 | 0.76 | 0.82 | 0.9 | 0.77 | 0.75 | 0.62 | 0.89 | 0.91 |
| PE** | 0.215 | 0.413 | 0.528 | 0.599 | 0.407 | 0.543 | 0.523 | 0.551 | 0.648 | 0.463 | 0.421 | 0.217 | 0.525 | 0.825 | 0.928 |
| Typical Paternity Index | 1.06 | 1.61 | 2.09 | 2.5 | 1.59 | 2.17 | 2.54 | 1.45 | 2.88 | 1.8 | 1.72 | 1.05 | 2.05 | 5.83 | 14 |
| No. of Alleles | 8 | 9 | 6 | 5 | 11 | 12 | 5 | 8 | 15 | 9 | 8 | 6 | 11 | 14 |
| Het obs | 0.422 | 0.724 | 0.724 | 0.737 | 0.557 | 0.684 | 0.692 | 0.513 | 0.770 | 0.788 | 0.701 | 0.518 | 0.785 | 0.909 | 0.964 |
| Het exp | 0.744 | 0.787 | 0.733 | 0.726 | 0.590 | 0.764 | 0.782 | 0.575 | 0.821 | 0.901 | 0.68 | 0.615 | 0.734 | 0.932 | 0.917 |
| PHWE | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 | P < 0.001 |

The conclusion is that II-3, II-4, II-6 and II-8 are not affected and were reported to the IVF center to decide which to be transferred.

Figure 5. Schematic representation of a PGD result for beta-thalassemia and aneuploidy. As it is shown the assigned haplotypes are shown underneath each blastomere, parents and the affected child. The order of corresponding STR markers are shown on left. I-1 (father) is a carrier of IVSI-6 mutation and I-2 (mother) is carrier for IVSI-1. II-1 is the affected child of the family. II-2 is a male who carries IVSI-1 mutation, II-3 is normal male, II-4 is normal female but who is affected with trisomy 21, II-5 is a normal female but is affected with trisomy 21. The conclusion is that II-3, II-4, II-6 and II-8 are not affected and were reported to the IVF center to decide which to be transferred.
we do not force them. Regarding embryo transfer, in most PGD cases (except in few hemophilia A or B cases in which families have insisted in not transferring carrier female embryos) we suggest that both homozygous normal and heterozygote carriers’ embryos be transferred.

We showed that this newly released HapScreen kit can overcome these problems since different tetra-nucleotide repeat markers with a high rate of heterozygosity have been added into the kit to reduce the rate of stutter artifacts which is usually seen in dinucleotide repeat units\(^41\). In addition, to minimize the possibility of miscesis recombination, physical distances of newly selected markers to the gene have been chosen to be less than 1Mbp. To further assess the suitability of the markers, allele frequency and heterozygosity of each STR marker were calculated in at least 100 unrelated individuals.

Using multiplex-PCR in linkage analysis, not only requires less time, reagents and labor work; it also decreases the sampling error rate. More importantly, it compensates the problem of insufficiency of blastomeric DNA used in PGD. Determining sample authenticity is an important issue in PND and PGD. There is a 50% similarity of haplotypes between the fetus and the mother; therefore, it is of great significance to confirm that the sample belongs to the fetus and it is not merely a result of maternal cell contamination. By adding nine markers from different chromosomes in addition to seven markers linked to the \(\beta\)-globin gene, it seems very unlikely that two individuals would have the same haplotype.

Errors can arise in every stage of CVS or amniocentesis in twin pregnancies. Therefore, the kit has a tool to differentiate between fetuses in twin or multiple pregnancies or between samples which have under gone PND testing (i.e. parental, sibs and fetuses’), to reduce the rate of errors. By choosing multiple markers from different chromosomes (i.e. chromosomes 6, 21, 18, 13, X and Y), the chance of observing the same haplotype in different individuals would be reduced. Therefore, this important feature would be very helpful to rule out maternal contamination, investigating sample authenticity and differentiation of fetal samples in multiple pregnancies. It can also confirm triploidy or uniparental disomy.

To achieve these goals, the manufacturer could have selected these markers from markers that are used in different human identification kits (e.g. GT-Detector human identification kit, GT), but they have preferred to choose them from chromosomes that are major cause of common aneuploidies\(^42\). In addition, to achieve the above mentioned goals, these markers allow early screening for common aneuploidies and sex determination in fetal samples and blastomeres cells.

We have been able to use HapScreen in several hundreds of our PND and PGD cases with no shortcomings and we think it adds credibility to every PND and PGD and also increases diagnostic accuracy and peace of mind in a discipline prone to misdiagnosis.

Data Availability
The authors confirm that the data supporting the findings of this study are available within the article and more information that support the findings of this study will be available on request from the corresponding.

References
1. Galanello, R. & Origa, R. Beta-thalassemia. J. Orphanet journal of rare diseases. 5, 11, https://doi.org/10.1186/1750-1172-5-11 (2010).
2. Rathod, D. A. et al. Usefulness of cell counter–based parameters and formulas in detection of \(\beta\)-thalassemia trait in areas of high prevalence. J. American Journal of Clinical Pathology. 128, 585–589 (2007).
3. Hossain, M. S. et al. Thalassemias in South Asia: clinical lessons learnt from Bangladesh. J. Orphanet journal of rare diseases. 12, 93 (2017).
4. Abolghasemi, H. et al. Thalassemia in Iran: epidemiology, prevention, and management. J. Pediatric Hematology/Oncology. 29, 233–238 (2007).
5. Fallah, M. S., Samavat, A. & Zeinali, S. Iranian national program for the prevention of thalassemia and prenatal diagnosis: mandatory premarital screening and legal medical abortion. J. Prenatal Diagnosis. 29, 1285–1286 (2009).
6. Samavat, A. & Modell, B. Iranian national thalassemia screening programme. J. BMJ. 329, 1134–1137 (2004).
7. Maryam, E., Azarkeivan, A., Fallah, M. S. & Zeinali, S. A large cohort study of genotype and phenotype correlations of beta-thalassemia in Iranian population. J. International journal of hematology- oncology and stem cell research. 9, 198–202 (2015).
8. Figueira, R. C. et al. Preimplantation diagnosis for \(\beta\)-thalassemia combined with HLA matching: first “savior sibling” is born after embryo selection in Brazil. J. Journal of assisted reproduction and genetics. 29, 1305–1309 (2012).
9. Cooper, A. R. & Jungheim, E. S. Preimplantation genetic testing: indications and controversies. J. Clinics in laboratory medicine. 30, 519–531 (2010).
10. Vermeesch, J. R., Voet, T. & Devriendt, K. Prenatal and pre-implantation genetic diagnosis. J. Nature Reviews Genetics. 17, 643–656 (2016).
11. Cirigliano, V. et al. Rapid prenatal diagnosis by QF-PCR: evaluation of 30,000 consecutive clinical samples and future applications. J. Annals of the New York Academy of Sciences. 1075, 288–298 (2006).
12. Gaib, J. N. Simple salting-out method for genomic DNA extraction from whole blood. J. Tikrit Journal of Pure Science. 16, 9–11 (2011).
13. Benson, G. Tandem repeats finder: a program to analyze DNA sequences. J. Nucleic acids research. 27, 573–580 (1999).
14. Lima, A. O. & Garcés, S. P. Intragenic primer design: Bringing bioinformatics tools to the class. J. Biochemistry and Molecular Biology Education. 34, 332–337 (2006).
15. Fisher, R. A. Standard Calculator: for Evaluating a Blood-Group System. J. Heredity. 5, 95–102 (1911).
16. Fung, W. K., Chung, Y.-K. & Wong, D.-M. Power of exclusion revisited: probability of excluding relatives of the true father from paternity. J. International journal of legal medicine. 116, 64–67 (2002).
17. Ristow, P. G. & D’Amato, M. E. Forensic statistics analysis toolbox (FORSTAT): A streamlined workflow for forensic statistics. J. Forensic Science International: Genetics Supplement Series 6, e52–e54 (2017).
18. Peakall, R. & Smouse, P. E. GENALEX 6: genetic analysis in Excel. Population genetic software for teaching and research. J. Molecular ecology notes. 6, 288–295 (2006).
19. Teimourian, S., Khatibi, T., Pourfarzad, F., Jalil-Nejad, S. & Azad, M. Amplification Refractory Mutation System (ARMS) and reverse hybridization in the detection of beta-thalassemia mutations. J. Archives of Iranian Medicine. 4, 165–170 (2001).
20. Vrettou, C., Traeger-Synodinos, J., Tzetis, M., Malamis, G. & Kanavakis, E. Rapid screening of multiple \(\beta\)-globin gene mutations by real-time PCR on the LightCycler: application to carrier screening and prenatal diagnosis of thalassemia syndromes. J. Clinical chemistry. 49, 769–776 (2003).
21. Kan, Y. W., Lee, K. Y., Furbetta, M., Angius, A. & Cao, A. Polymorphism of DNA sequence in the \(\beta\)-globin gene region: application to prenatal diagnosis of \(\beta\) thalassemia in Sardinia. J. New England Journal of Medicine. 302, 185–188 (1980).
Author Contributions

Z. Sharifi carried out the major part of the design and the study as well as writing the manuscript. F. Rahiminejad carried out the sequence tests of PND part. A. Joudaki carried out the aneuploidy design and data analysis. A. Sarhadi Bandehi carried out the most of the fragment analysis and interpretations. H. Farahzadi performed the most of data analysis and drawing the figures. Y. Keshvar carried out the PND part. F. Golnabi carried out the DNA extraction. S. Naderi, R. Yazdani and M. Shafaat carried out the PND part. S. Ghadami carried out the major part of the design and the study as well as writing the manuscript. F. Rahiminejad was co-supervisor of the project, helping in the interpretation of results, editing the manuscript. S. Zeinali was supervising the project, helping in the design of the kit and editing the manuscript. All authors read and approved the paper.

Additional Information

Competing Interests: S. Zeinali: This author has shares in the Genetek Company and also has provided assistance and financial support for the development of Hapscreen, Aneusure and GT-Detector kits. Z. Sharifi: This author had major role in developing the kit but has no share or stock in the company. Other authors have no conflicting interest nor have any shares or stocks in the company which is manufacturing or marketing the Hapscreen, Aneusure and GT-Detector kits.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019